Bone Biologics (BBLG) Director Siddhesh Angle Receives Award

What Happened

• Siddhesh Rajendra Angle, a director of Bone Biologics Corp (BBLG), was granted a derivative award covering 113,896 shares on 2026-09-28. The Form 4 reports a $0.00 price for the award (derivative), so the filing shows $0 value for the transaction itself.
• The award was made under the Bone Biologics Corporation 2015 Equity Incentive Plan and is reported as exempt under Rule 16b-3. This is a compensation/award transaction (not an open-market purchase or sale).

Key Details

• Transaction date: 2026-09-28; Form 4 filed: 2026-09-30 (timely filed).
• Reported transaction: 113,896 shares; transaction price $0.00 (derivative award/option).
• Footnotes: F1 — grant under 2015 Equity Incentive Plan; vesting described as four equal quarterly installments (unless award notice provides otherwise). F2 — the option is noted as fully exercisable as of the report date.
• Shares owned after the transaction: not specified in the provided excerpt of the filing.
• Filing accession: 0001493152-26-045147.

Context

• This was an equity award (derivative/option), a form of compensation for an insider. It is not a cash purchase or sale of existing shares.
• The $0.00 reported exercise price means, if exercisable, conversion to shares would not require a cash exercise payment; actual economic value depends on the company’s market price and any applicable vesting or other award conditions.
• No 10b5-1 plan, gift, sale, or tax-withholding actions are indicated in the provided information.